Mosunetuzumab And Same-day Pegfilgrastim w/ ddAC
Jan 05, 2023•21 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
New Year - New Drug, mosunetuzumab (a CD3-CD20 T-cell engager) is approved for r/r Follicular Lymphoma.
And an intriguing retrospective cohort study found a higher rate of neutropenia with same-day pegfilgrastim in patients receiving dose-dense AC. Link: https://doi.org/10.1177/10781552221148116
For the best experience, listen in Metacast app for iOS or Android